Extract
We were fascinated by the recent paper from Currow et al. [1], which described the largest randomised controlled trial of an antidepressant in the treatment of chronic refractory breathlessness. This study was important as there are few pharmacological treatments available for chronic breathlessness. In this group there is an unmet clinical need for treatments that target symptoms. The study's theoretical basis was well supported by preliminary data. However, no difference was observed between sertraline and placebo for the primary outcome measure, the improvement in breathlessness intensity.
Abstract
Harnessing the placebo response may benefit patients with chronic breathlessness http://ow.ly/1BTK30naRZc
Footnotes
Conflict of interest: K. Pattinson reports personal fees for consultancy from Nektar Pharmaceuticals, outside the submitted work; and is supported by the National Institute for Health Research, Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford.
Conflict of interest: V. Wanigasekera has nothing to disclose.
- Received November 22, 2018.
- Accepted November 25, 2018.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
